BioInvent Using New Screening Platforms To Identify Novel IO Targets
Biotech Boasts Five Compounds Being Examined Across Six Studies
Swedish biotech BioInvent uses its extensive antibody library to identify new immuno-oncology targets and translate these into therapies. Following the delivery of some impressive early-stage research at the annual Society for Immunotherapy for Cancer conference, CEO Martin Welschof caught up with In Vivo to share more about the firm’s story so far.
